4-methoxy-1H-indole-2-carboxamide | 213682-24-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-methoxy-1H-indole-2-carboxamide
• 英文别名: 4-methoxy-1H-indolecarboxamide；4-methoxy-indole-2-carboxamide
• CAS: 213682-24-7
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD07364585
• 分子量: 190.202
• InChiKey: RSIGFRGWKDOWPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  68.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methoxy-1H-indole-2-carboxamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 (4-methoxy-1H-indol-2-yl)methanamine
  参考文献：
  名称：

  2-[N-Acylamino(C₁−C₃)alkyl]indoles as MT₁ Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists

  摘要：

  The synthesis of several novel indole melatonin analogues substituted at the 2-position with acylaminomethyl (8-11), acylaminoethyl (5a-k), or acylaminopropyl (13) side chains is reported. On the basis of a novel in vitro functional assay (specific binding of [S-35]GTP gamma S), which can discriminate agonist from partial agonist, antagonist, and inverse agonist ligands, Ba,g,h,j and 13 were shown to be partial agonists, 5d,e and 8-11 competitive antagonists, and 5b,c,k putative inverse agonists. Binding and functional assays were performed on cloned human MT1 receptor. Structure-activity relationship considerations indicate that N-[1-aryl-2-(4-methoxy-1H-indol-2-yl)(C-1-C-2)alkyl]alkanamides represent a lead structure for this type of ligands.

  DOI：

  10.1021/jm970721h
• 作为产物：
  描述：

  4-甲氧吲哚-2-羧酸甲脂 在 氢氧化钾 、 氯化亚砜 、 氨 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 38.0h， 生成 4-methoxy-1H-indole-2-carboxamide
  参考文献：
  名称：

  2-[N-Acylamino(C₁−C₃)alkyl]indoles as MT₁ Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists

  摘要：

  The synthesis of several novel indole melatonin analogues substituted at the 2-position with acylaminomethyl (8-11), acylaminoethyl (5a-k), or acylaminopropyl (13) side chains is reported. On the basis of a novel in vitro functional assay (specific binding of [S-35]GTP gamma S), which can discriminate agonist from partial agonist, antagonist, and inverse agonist ligands, Ba,g,h,j and 13 were shown to be partial agonists, 5d,e and 8-11 competitive antagonists, and 5b,c,k putative inverse agonists. Binding and functional assays were performed on cloned human MT1 receptor. Structure-activity relationship considerations indicate that N-[1-aryl-2-(4-methoxy-1H-indol-2-yl)(C-1-C-2)alkyl]alkanamides represent a lead structure for this type of ligands.

  DOI：

  10.1021/jm970721h

文献信息

• NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：EP4001279A1

  公开（公告）日：2022-05-25

  The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

  本发明公开了式（Ia）化合物及其药学上可接受的盐类： 其可抑制冠状病毒的复制活性。本发明进一步涉及包含式（Ia）化合物或其药学上可接受的盐的药物组合物，以及治疗或预防有需要的受试者冠状病毒感染的方法，包括向受试者施用治疗有效量的式（Ia）化合物或其药学上可接受的盐。
• 一种2-芳香胺基嘧啶类化合物及其制备方法与应用
  申请人：北京英飞智药科技有限公司

  公开号：CN117800953A

  公开（公告）日：2024-04-02

  本申请涉及生物医药技术领域，具体公开了一种2‑芳香胺基嘧啶类化合物及其制备方法与应用。本申请提供一种2‑芳香胺基嘧啶类化合物，该化合物为通式I所示的化合物或其药学上可接受的盐、异构体、溶剂化物、水合物、前药或同位素衍生物；通式I的结构式为：#imgabs0#本申请提供的2‑芳香胺基嘧啶类化合物对PLK1的活性具有很强的抑制作用，有望开发成为新型抗肿瘤药物。
• INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
  申请人：Pardes Biosciences, Inc.

  公开号：US20220162194A1

  公开（公告）日：2022-05-26

  The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.